B. Düsterberg
About
B. Düsterberg is a scholar working on Public Health, Environmental and Occupational Health, Endocrinology, Diabetes and Metabolism and Reproductive Medicine.
According to data from OpenAlex, B. Düsterberg has authored 39 papers receiving a total of 968 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Public Health, Environmental and Occupational Health, 11 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Reproductive Medicine. Recurrent topics in B. Düsterberg's work include Reproductive Health and Contraception (15 papers), Hormonal and reproductive studies (8 papers) and Estrogen and related hormone effects (6 papers). B. Düsterberg is often cited by papers focused on Reproductive Health and Contraception (15 papers), Hormonal and reproductive studies (8 papers) and Estrogen and related hormone effects (6 papers). B. Düsterberg collaborates with scholars based in Germany, Austria and Denmark. B. Düsterberg's co-authors include Jan Endrikat, Christoph Gerlinger, Ulrich Müller, W. Schmidt, U. Täuber, Frank Lüdicke, Jürgen Spona, Wilfried Feichtinger, Helen Sullivan and Max Elstein and has published in prestigious journals such as American Journal of Obstetrics and Gynecology, Drug Metabolism and Disposition and European Journal of Endocrinology.
In The Last Decade
B. Düsterberg
36 papers receiving 881 citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| B. Düsterberg Germany | 20 | 582 | 304 | 236 | 132 | 118 | 39 | 968 | ||
| Göran Cullberg Sweden | 18 | 288 0.5× | 367 1.2× | 461 2.0× | 78 0.6× | 239 2.0× | 36 | 916 | ||
| Ulf Larsson‐Cohn Sweden | 25 | 467 0.8× | 310 1.0× | 728 3.1× | 173 1.3× | 425 3.6× | 61 | 1.5k | ||
| H. P. Zahradnik Germany | 19 | 234 0.4× | 163 0.5× | 81 0.3× | 185 1.4× | 115 1.0× | 58 | 875 | ||
| Shiva Safarinejad Iran | 18 | 228 0.4× | 380 1.3× | 99 0.4× | 111 0.8× | 121 1.0× | 24 | 918 | ||
| Miryam Asunción Spain | 7 | 714 1.2× | 1.1k 3.6× | 280 1.2× | 97 0.7× | 62 0.5× | 11 | 1.4k | ||
| Victor A. Drill United States | 15 | 137 0.2× | 67 0.2× | 129 0.5× | 64 0.5× | 112 0.9× | 47 | 846 | ||
| Hartmut Blode Germany | 14 | 192 0.3× | 82 0.3× | 113 0.5× | 47 0.4× | 94 0.8× | 26 | 459 | ||
| Judith M. A. Emmen Netherlands | 17 | 715 1.2× | 295 1.0× | 142 0.6× | 148 1.1× | 349 3.0× | 27 | 1.6k | ||
| Elsy Velázquez Venezuela | 6 | 512 0.9× | 730 2.4× | 376 1.6× | 87 0.7× | 22 0.2× | 7 | 1.0k | ||
| Hyewon Chung South Korea | 16 | 121 0.2× | 160 0.5× | 65 0.3× | 57 0.4× | 35 0.3× | 45 | 592 |
Countries citing papers authored by B. Düsterberg
Since
Specialization
Citations
This map shows the geographic impact of B. Düsterberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Düsterberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Düsterberg more than expected).
Fields of papers citing papers by B. Düsterberg
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by B. Düsterberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Düsterberg. The network helps show where B. Düsterberg may publish in the future.
Co-authorship network of co-authors of B. Düsterberg
This figure shows the co-authorship network connecting the top 25 collaborators of B. Düsterberg. A scholar is included among the top collaborators of B. Düsterberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Düsterberg. B. Düsterberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Endrikat, Jan, Christoph Gerlinger, Stephanie A Richard, Peter Rosenbaum, & B. Düsterberg. (2011). Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception. 84(6). 549–557.
2.
Skouby, Sven O., Jan Endrikat, B. Düsterberg, et al.. (2005). A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel. Contraception. 71(2). 111–117.
3.
Jespersen, Jørgen, Jan Endrikat, B. Düsterberg, et al.. (2005). A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 μg of ethinylestradiol and 100 μg of levonorgestrel with 30 μg of ethinylestradiol and 100 μg of levonorgestrel. Contraception. 72(2). 98–104.
4.
Endrikat, Jan, et al.. (2004). A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 μg or 30 μg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception. 69(3). 179–187.
5.
Klipping, Christine, et al.. (2002). An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception. 65(3). 215–221.
6.
Endrikat, Jan, et al.. (2001). Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 20 μg ethinyl estradiol and 150 μg desogestrel. Contraception. 64(3). 201–207.
7.
Endrikat, Jan, Christine Klipping, Christoph Gerlinger, et al.. (2001). A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 30 μg ethinyl estradiol and 75 μg gestodene on hemostatic variables, lipids, and carbohydrate metabolism. Contraception. 64(4). 235–241.
8.
Endrikat, Jan, et al.. (2001). Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 μg ethinyl estradiol and 75 μg gestodene. Contraception. 64(2). 99–105.
9.
Endrikat, Jan, M Noah, Christoph Gerlinger, et al.. (2001). Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations. Contraception. 64(4). 217–222.
10.
Endrikat, Jan, et al.. (1999). Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception. 60(5). 269–274.
11.
Winkler, Ulrich, Alexander Schindler, Jan Endrikat, & B. Düsterberg. (1996). A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol. Contraception. 53(2). 75–84.
12.
Düsterberg, B., et al.. (1996). A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecological Endocrinology. 10(1). 33–39.
13.
Spona, Jürgen, Max Elstein, Wilfried Feichtinger, et al.. (1996). Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 54(2). 71–77.
14.
Endrikat, Jan, et al.. (1995). A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel, with respect to efficacy, cycle control and tolerance. Contraception. 52(4). 229–235.
15.
Düsterberg, B., et al.. (1995). The effect on blood pressure of a monophasic oral contraceptive containing ethinylestradiol and gestodene. Contraception. 51(6). 335–339.
16.
Kŕause, W., et al.. (1993). Biotransformation of proterguride in the perfused rat liver.. Drug Metabolism and Disposition. 21(2). 203–208.
17.
Spona, J., et al.. (1993). Inhibition of ovulation by a triphasic gestodene-containing oral contraceptive. Advances in Contraception. 9(3). 187–194.
18.
Düsterberg, B. & K. Brill. (1990). Clinical acceptability of monophasic gestodene. American Journal of Obstetrics and Gynecology. 163(4). 1398–1404.
19.
Pulkkinen, M.O., et al.. (1984). Norethisterone acetate and ethinylestradiol in early human pregnancy. Teratology. 29(2). 241–249.
20.
Düsterberg, B., M. Hümpel, & Ulrich Speck. (1981). Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys. Contraception. 24(6). 673–683.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Göran Cullberg Breakdown of academic impact, for papers by Ulf Larsson‐Cohn Breakdown of academic impact, for papers by H. P. Zahradnik Breakdown of academic impact, for papers by Shiva Safarinejad Breakdown of academic impact, for papers by Miryam Asunción Breakdown of academic impact, for papers by Victor A. Drill Breakdown of academic impact, for papers by Hartmut Blode Breakdown of academic impact, for papers by Judith M. A. Emmen Breakdown of academic impact, for papers by Elsy Velázquez Breakdown of academic impact, for papers by Hyewon Chung